08:23 AM EDT, 08/12/2024 (MT Newswires) -- ScPharmaceuticals ( SCPH ) said Monday its pharmacokinetic study of SCP-111 administered through an autoinjector as an alternative to the current on-body infusor used with the company's Furoscix achieved its goals.

SCP-111, an investigational formulation of furosemide, demonstrated a bioavailability of 107.3%, falling within the 90% confidence interval limit of 80% to 125%, according to the company.

Treatment with SCP-111 via autoinjector also showed similar urine output as well as urinary sodium and potassium excretion compared with furosemide via intravenous therapy, the company added.

The company said it plans to submit a supplemental new drug application to the US Food and Drug Administration by yearend.

Shares of scPharmaceuticals were down more than 10% in recent premarket activity.

Price: 3.8800, Change: -0.45, Percent Change: -10.39